1 Cemiplimab, an anti–PD-1 antibody, is approved for the treatment of adults with locally advanced or metastatic CSCC who are not candidates for curative surgery or radiotherapy.2 Recently, cemiplimab received approval for the adjuvant treatment of adults with CSCC at high risk of recurrence after surgery and radiotherapy.2,3 Up-front surgery with or without adjuvant radiotherapy is the standard-of-care treatment of cutaneous squamous cell carcinoma (CSCC).
Neil Gross
As seen in:
MSN Malaysia,
The New York Times,
Nature,
Wiley Online Library,
The Atlantic,
Globe Advisor,
MDPI,
The Globe and Mail,
Flipboard,
JAMA Oncology
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Neil
Contact Neil, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack